- |||||||||| solitomab (AMG 110) / Amgen
Journal: Genome-wide association study and genomic selection of spike-related traits in bread wheat. (Pubmed Central) - May 15, 2024
Additionally, the eight stable and major MTAs, including MTA259, MTA64, MTA66, MTA94, MTA110, MTA165, MTA180, and MTA164, were converted into cost-effective and efficient detection markers. This study provided valuable genetic resources and reliable molecular markers for wheat breeding programs.
- |||||||||| solitomab (AMG 110) / Amgen
Journal: Studies on a new antimicrobial peptide from Vibrio proteolyticus MT110. (Pubmed Central) - May 15, 2023
The physicochemical properties and stability in wide pH and temperature ranges showed the potential of peptide-MT110 for its development as a drug candidate. This is believed to be the first report on an AMP from Vibrio proteolyticus.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), solitomab (AMG 110) / Amgen
A 30 PDX Panel of 3D in vitro tumor models identifies responders to Pembrolizumab and Solitomab. (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1750;
Endpoints including tumor size and killing highlighted PDX responders to both Pembrolizumab and Solitomab. These data highlight the ability to screen various immunotherapy compounds in a standardized 3D PDX in vitro panel for determining antitumor effect in drug discovery and translational research to enhance patient outcomes.
- |||||||||| Lymphomun (FBTA05) / Trion Pharma, NeoPharm, solitomab (AMG 110) / Amgen, Kalbitor (ecallantide) / Takeda
Journal: Immunotargeting and therapy of cancer by advanced multivalence antibody scaffolds. (Pubmed Central) - Oct 14, 2021
Novel multivalent Ab scaffolds (e.g., MDX-447, MT110, CD20Bi, TF2, and FBTA05) and mimetic Abs (e.g., Adnectin, DARPins, Ecallantide) offer improved pharmacokinetic and pharmacodynamic properties. Here, we discuss the avidity and multivalency and provide comprehensive insights into advanced Ab scaffolds used for immunotargeting and therapy of cancer.
- |||||||||| solitomab (AMG 110) / Amgen
Journal, IO biomarker: EpCAM expression in esophageal cancer and its correlation with immunotherapy of solitomab. (Pubmed Central) - May 21, 2021
Further, EC Eca109 cell spheres have a high expression level of EpCAM, and EpCAM may be one of the markers of EC stem cells. Therefore, EpCAM could be used as a potential molecular target of immunotherapy for EC, and solitomab may become an effective immunotherapeutic drug for chemotherapy-resistant EC cells.
- |||||||||| solitomab (AMG 110) / Amgen
Journal: Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm. (Pubmed Central) - Mar 10, 2021
PET images and ex vivo biodistribution in immunocompetent mice with [Zr]Zr-DFO-N-suc-muS110, targeting mouse CD3 (dissociation constant [K], 2.9 nM) and mouse epithelial cell adhesion molecule (EpCAM; K, 21 nM), and with [Zr]Zr-DFO-N-suc-hyS110, targeting only mouse CD3 (K, 2.9 nM), showed uptake in the tumor, spleen, and other lymphoid organs, whereas the human-specific control BiTE [Zr]Zr-DFO-N-suc-AMG 110 showed similar tumor uptake but lacked spleen uptake...Significance: 89Zr-muS110 biodistribution is mainly dependent on the T-cell targeting arm with limited contribution of its second arm, targeting EpCAM. These findings highlight the need for extensive biodistribution studies of novel bispecific constructs as results might have implications for their respective drug development and clinical translation.
- |||||||||| solitomab (AMG 110) / Amgen
Journal: TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells. (Pubmed Central) - Dec 16, 2020
By reinvigorating dysfunctional γδ T cells and promoting them to accumulate at tumor sites, the combined use of TIM-3 inhibitor and MT110 could further enhance the anti-tumor effect of the adoptively transfused γδ T cells. These results may have clinical implications for the design of new translational anti-tumor regimens aimed at combining checkpoint blockade and immune cell redirection.
- |||||||||| solitomab (AMG 110) / Amgen
Eradication of EpCAM expressing solid tumors by low-affinity CAR T cells (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_4230;
Low-affinity EpCAM targeting CAR T cells demonstrated durable antitumor activity against various tumor models in vivo. To enhance safety and therapeutic efficacy, micromolar affinity anti-EpCAM CAR T cells are currently being evaluated to limit cell killing to EpCAM-positive tumor cells while sparing normal cells with basal levels of EpCAM expression.
- |||||||||| solitomab (AMG 110) / Amgen
Trial completion, Metastases: MT110-101: Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer (clinicaltrials.gov) - Jan 13, 2015
P1, N=65, Completed,
CED of panobinostat warrants clinical investigation in patients with DIPG. Active, not recruiting --> Completed
- |||||||||| solitomab (AMG 110) / Amgen
Enrollment closed, Metastases: MT110-101: Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer (clinicaltrials.gov) - Jan 21, 2014
P1, N=70, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| solitomab (AMG 110) / Amgen
Enrollment change, Metastases: MT110-101: Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer (clinicaltrials.gov) - Sep 11, 2011
P1, N=70, Active, not recruiting,
Recruiting --> Active, not recruiting N=50 --> 70
|
